TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9644644

Group type: EXPERIMENTAL
Intervention: Indium scans and removal of clotted grafts in patients with fever or sepsis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Indium scans and removal of clotted grafts in asymptomatic control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bacterial cultures of recovered surgical material and blood
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chart review of past infectious episodes
Number of subjects: 20
Study: 8181318

Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure ventilatory support system (BiPAP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 22
Study: 3371392

Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol, 100 mg once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 100 mg once daily
Number of subjects: 27
Study: 31200629

Group type: EXPERIMENTAL
Intervention: Dynamic scapular recognition exercise using a wireless biofeedback system
Number of subjects: 66

Group type: COMPARATOR
Intervention: Active range-of-motion (ROM) exercises of the sound upper limb (Control)
Number of subjects: 66
Study: 30127136

Group type: EXPERIMENTAL
Intervention: ARK-30 autorefractor without cycloplegia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ARK-30 autorefractor under cycloplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retinoscopy
Number of subjects: 30
Study: 27335139

Group type: EXPERIMENTAL
Intervention: Pregnant women (n = 26)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lactating women (n = 28)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All participants (n = 75)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control women (n = 21)
Number of subjects: 75
Study: 24709242

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 22033512

Group type: EXPERIMENTAL
Intervention: Severe-heavy (S-H)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Severe-moderate (S-M)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Severe-light (S-L)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Severe-intensity constant-work-rate (S-CWR)
Number of subjects: 7
Study: 20507557

Group type: EXPERIMENTAL
Intervention: On-demand relaparotomy strategy
Number of subjects: 229

Group type: COMPARATOR
Intervention: Planned relaparotomy strategy
Number of subjects: 229
Study: 18257187

Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no catgut implanted)
Number of subjects: 26
Study: 16200558

Group type: EXPERIMENTAL
Intervention: High-to-low payment card format
Number of subjects: 314

Group type: COMPARATOR
Intervention: Low-to-high payment card format
Number of subjects: 314

Group type: COMPARATOR
Intervention: Randomly shuffled payment card format
Number of subjects: 314

Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 314

Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 314
Study: 12920415

Group type: EXPERIMENTAL
Intervention: Typical antipsychotic discontinuation (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Typical antipsychotic continuation (n = 12)
Number of subjects: 24
Study: 10902990

Group type: EXPERIMENTAL
Intervention: Energy supplement (E) = 1171 kJoule + 12 mg iron
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (M) = 12 mg iron + 209 kJ
Number of subjects: 136

Group type: COMPARATOR
Intervention: Supplement (S) = 104 kJ
Number of subjects: 136
Study: 9371853

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study: 1590284

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine sulfate (SRMS) tablets, 30 mg every 12 hours
Number of subjects: 27

Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) solution, same mg/24 hours dose, every 4 hours
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine sulfate (SRMS) tablets
Number of subjects: 27

Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) solution
Number of subjects: 27
Study: 4003636

Group type: EXPERIMENTAL
Intervention: Skills intervention to prevent cigarette smoking
Number of subjects: 689

Group type: COMPARATOR
Intervention: Health information alone
Number of subjects: 689

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 689
Study: 29733008

Group type: EXPERIMENTAL
Intervention: Direct imprint glove-sampling methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sponge stick glove-sampling methodology
Number of subjects: 0
Study: 26706667

Group type: EXPERIMENTAL
Intervention: Culturally-tailored contingency management intervention for alcohol abstinence
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control condition (receiving reinforcers for attending study visits regardless of alcohol use)
Number of subjects: 400
Study: 24853275

Group type: EXPERIMENTAL
Intervention: Preoperative TACE
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (non-TACE)
Number of subjects: 35
Study: 22458978

Group type: EXPERIMENTAL
Intervention: E-learning program (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 30
Study: 20457286

Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polyethylene glycol
Number of subjects: 40
Study: 17681999

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional high-resolution imaging
Number of subjects: 401
Study: 15755234

Group type: EXPERIMENTAL
Intervention: Full IMB session
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Motivational counseling
Number of subjects: 625
Study: 12721256

Group type: EXPERIMENTAL
Intervention: Delayed Intensification (DI) phase of therapy for 7 weeks
Number of subjects: 778

Group type: COMPARATOR
Intervention: Standard regimen without Delayed Intensification
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Overall survival for eligible patients
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Delayed Intensification (DI) phase of therapy
Number of subjects: 778
Study: 10474123

Group type: EXPERIMENTAL
Intervention: Pulsatile GnRH infusion (100 ng/kg i.v. every 90 min for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 10
Study: 8709374

Group type: EXPERIMENTAL
Intervention: Transurethral resection plus mitomycin C (20 mg/50 ml sodium chloride, every 2 weeks during year 1 and once a month during year 2)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Transurethral resection plus bacillus Calmette-Guerin (BCG) (120 mg/50 ml sodium chloride, instilled once a week for 6 weeks and once a month for 4 months)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Transurethral resection only
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: All therapy groups (mitomycin C, BCG, and transurethral resection only)
Number of subjects: 337
Study: 1855607

Group type: EXPERIMENTAL
Intervention: 500 mg of intrapartum ampicillin intravenously
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 6881978

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy using Nocardia rubra cell wall skeleton
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Stage III and P.S. 0+1+2 patients
Number of subjects: 41
Study: 30794953

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol with HMG and low dose (100IU/day) hCG
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Short GnRH-agonist protocol with HMG and low dose (100IU/day) hCG
Number of subjects: 240
Study: 28462571

Group type: EXPERIMENTAL
Intervention: Combined endurance running and strength training program once a week (ES30)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined endurance running and strength training program twice a week (ES60)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Endurance running (E)
Number of subjects: 41
Study: 27082736

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of anti-VEGF drugs (ranibizumab and/or aflibercept)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cumulative number of aflibercept injections
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cumulative number of intravitreal injections of overall anti-VEGF drugs
Number of subjects: 45
Study: 24902075

Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 60
Study: 22021122

Group type: EXPERIMENTAL
Intervention: Infrahyoid flap reconstruction
Number of subjects: 18

Group type: COMPARATOR
Intervention: Free radial forearm flap reconstruction
Number of subjects: 18
Study: 19786130

Group type: EXPERIMENTAL
Intervention: SB-423557 (daily oral administration)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: SB-423562 (single intravenous dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: SB-423557 (single oral dose)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: SB-423557 (higher doses)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study: 17479288

Group type: EXPERIMENTAL
Intervention: Topotecan (1.0 mg/m(2)/day 168‐h continuous infusion), cyclophosphamide (100 mg/m(2)/day 1‐h infusion days 1‐7), etoposide (100 mg/m(2)/day 1‐h infusion days 8‐10)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topotecan, cyclophosphamide, and etoposide
Number of subjects: 42
Study: 15209391

Group type: EXPERIMENTAL
Intervention: Vaginal washing with povidone iodine and insertion of chloramphenicol vaginal tablets in women with IL-8 elevations (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (Group A, no treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (Group C, treatment not specified)
Number of subjects: 0
Study: 11668157

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia
Number of subjects: 6163
Study: 9830832

Group type: EXPERIMENTAL
Intervention: L-glutamine (GLN) 0.03 g.kg body mass‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-glutamine (GLN)
Number of subjects: 10
Study: 8089357

Group type: EXPERIMENTAL
Intervention: Topical EMLA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moisturizer control
Number of subjects: 10
Study: 2724486

Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (3.4 g three times per day for 8 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31010435

Group type: EXPERIMENTAL
Intervention: Weight-for-length z-scores (WLZ) at 6 months
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Length-for-age z-scores (LAZ) at 6 months
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Weight-for-age z-scores (WAZ) at 6 months
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Incidence of presumed malaria from 6 to 18 months
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Incidence of clinical malaria from 6 to 18 months
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Incidence of RDT-confirmed malaria from 6 to 18 months
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Prevalence of malaria parasitaemia at 6 months
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Prevalence of malaria parasitaemia at 18 months
Number of subjects: 2723
Study: 28113069

Group type: EXPERIMENTAL
Intervention: Immediate catheter removal
Number of subjects: 31
Study: 25311913

Group type: EXPERIMENTAL
Intervention: Diclofenac (DF)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sulfamonomethoxine (SMM)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous administration of DF and SMM
Number of subjects: 5
Study: 24035203

Group type: EXPERIMENTAL
Intervention: NAVA (Neurally Adjusted Ventilatory Assist)
Number of subjects: 13

Group type: COMPARATOR
Intervention: PSV (Pressure Support Ventilation)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 13
Study: 21627974

Group type: EXPERIMENTAL
Intervention: Head‐Down Bed Rest (HDBR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sitting Control
Number of subjects: 22
Study: 19333672

Group type: EXPERIMENTAL
Intervention: Eccentric resistance exercise rehabilitation program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Traditional resistance exercise rehabilitation program
Number of subjects: 17
Study: 15883229

Group type: COMPARATOR
Intervention: Simvastatin 20 mg and placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg and ramipril 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ramipril 10 mg and placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined therapy (simvastatin 20 mg and ramipril 10 mg)
Number of subjects: 50
Study: 10333380

Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 34

Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 34
Study: 7486293

Group type: EXPERIMENTAL
Intervention: Extrapleural analgesia with 20 mL of 0.5% bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrpleural analgesia with 20 mL of 0.5% bupivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Extrapleural analgesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intrpleural analgesia
Number of subjects: 20
Study: 1663914

Group type: EXPERIMENTAL
Intervention: Sodium valproate (800 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6958473

Group type: EXPERIMENTAL
Intervention: Spacer devices with budesonide (low and high dosages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled terbutaline pretreatment
Number of subjects: 0
Study: 31658544

Group type: EXPERIMENTAL
Intervention: GDFM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional liquid management
Number of subjects: 30
Study: 29705115

Group type: EXPERIMENTAL
Intervention: Suction mask
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional mask
Number of subjects: 45
Study: 27207905

Group type: EXPERIMENTAL
Intervention: Perindopril 8mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perindopril 0, 4, 8, or 16mg/d
Number of subjects: 0
Study: 23990446

Group type: EXPERIMENTAL
Intervention: Robotic-assisted THA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional THA
Number of subjects: 100
Study: 22901830

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 118

Group type: COMPARATOR
Intervention: Gout patients
Number of subjects: 118
Study: 21057509

Group type: EXPERIMENTAL
Intervention: Exogenous attention with small stimuli and spatial uncertainty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous attention with large stimuli at one location (no uncertainty)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging experiment with wider attention fields
Number of subjects: 0
Study: 17653005

Group type: EXPERIMENTAL
Intervention: Xpert nitinol stents
Number of subjects: 47
Study: 15785303

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4 IU every other day for 3 months
Number of subjects: 12
Study: 11989050

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 60 mg i.v. 30 min before ESWL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous fentanyl 100 micrograms i.v. 3 min before ESWL
Number of subjects: 60
Study: 9803444

Group type: EXPERIMENTAL
Intervention: Antenatal TRH treatment
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control and TRH-treated groups
Number of subjects: 297
Study: 8929933

Group type: EXPERIMENTAL
Intervention: Residential services
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nonresidential services
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Both residential and nonresidential services
Number of subjects: 149
Study: 2551765

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 10 mg/kg.day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31349003

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily once or twice based on BMI) as an add-on to standard therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy (SAMA + SABA inhaled and ICS + LABA or ICS + LABA + LAMA)
Number of subjects: 60
Study: 28118422

Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual treatment (control)
Number of subjects: 37
Study: 25514794

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23898609

Group type: EXPERIMENTAL
Intervention: Muc1 expression in DSVPTC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: p63 expression in DSVPTC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cervical lymph node metastasis in DSVPTC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Muc1 expression in cervical lymph node metastasis group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: p63 expression in cervical lymph node metastasis group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation between Muc1 and p63 expression
Number of subjects: 60
Study: 21109771

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) and Valproic Acid (VPA) combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azacitidine (AZA) alone
Number of subjects: 0
Study: 21173560

Group type: EXPERIMENTAL
Intervention: Clevudine (30 mg once daily for more than 48 weeks)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg once daily for more than 48 weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Lamivudine (100 mg once daily for more than 48 weeks)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Clevudine
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 146

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 146
Study: 17925427

Group type: EXPERIMENTAL
Intervention: 16-W ramp protocol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 8-W ramp protocol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 8-W step protocol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 4-W ramp protocol
Number of subjects: 11

Group type: COMPARATOR
Intervention: All protocols
Number of subjects: 11
Study: 16113834

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 30
Study: 12009718

Group type: EXPERIMENTAL
Intervention: Urate concentration greater than 0.31 mmol.l(-1)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Urate concentration greater than 0.38 mmol.l(-1)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Raised urate in patients not on diuretics
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Urate
Number of subjects: 354
Study: 9856379

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-20 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Amlodipine and Lisinopril
Number of subjects: 71
Study: 7893026

Group type: EXPERIMENTAL
Intervention: Lidocaine with fentanyl (20 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lidocaine (plain)
Number of subjects: 8
Study: 2588996

Group type: EXPERIMENTAL
Intervention: 1:200,000 epinephrine with 10 ml of 1.5% lidocaine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Plain lidocaine (control)
Number of subjects: 2
Study: 939842

Group type: EXPERIMENTAL
Intervention: Behavioral intervention program (20 hours) involving child, parents, and teacher
Number of subjects: 32

Group type: COMPARATOR
Intervention: No contact control group
Number of subjects: 32
Study: 31806076

Group type: EXPERIMENTAL
Intervention: Modular CBT for youth anxiety
Number of subjects: 59

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 59
Study: 31405401

Group type: EXPERIMENTAL
Intervention: Integrated district level mental health care plan
Number of subjects: 245
Study: 27966032

Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 66% of individual electrical phosphene thresholds
Number of subjects: 14

Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 0% (sham)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 150% of individual electrical phosphene thresholds
Number of subjects: 14
Study: 26212090

Group type: EXPERIMENTAL
Intervention: Audiovisual informed group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Written informed group (control)
Number of subjects: 51
Study: 24261303

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 30
Study: 22093196

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg QD (2.5 mg in subjects with moderate/severe renal impairment)
Number of subjects: 16500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16500
Study: 19501222

Group type: EXPERIMENTAL
Intervention: Tubal sterilization through electrocoagulation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Application of mechanical clips
Number of subjects: 88
Study: 19681257

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips) and an anticavity toothpaste (Crest Cavity Protection)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo strips and a sodium fluoride (NaF) whitening dentifrice (Mentadent Whitening Toothpaste)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo strips and a sodium monofluorophosphate (MFP) whitening dentifrice (Rembrandt Low Abrasion Whitening Toothpaste)
Number of subjects: 46